MUDr. Petr Potměšil, Ph.D.

Department of Pharmacology 3FM CU

https://www.lf3.cuni.cz/3LF-400.html


Topic title

Pharmacokinetics

Pharmacovigilance in oncology


Description of scientific activity

Pharmacokinetics - Use of software MW-Pharm in therapeutic monitoring of levels of antidepressant or depot antipsychotic drugs


Pharmacovigilance in oncology - Incidence of serious or unexpected adverse events during treatment with capecitabine or 5-fluorouracil in patients screened for the presence of complete dihydropyrimidine dehydrogenase deficiency


Selected publications

P. Potměšil and R. Straková. Drug induced liver injury after switching from tamoxifen to anastrozole in a patient after breast cancer being treated for hypertension and diabetes. Therapeutic Advances in Chronic Disease 2020; 11: 1-11.


P. Potměšil. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice. Therapeutic Advances in Psychopharmacology 2019; 9: 1-11.


M. Kopeček and P. Potměšil. How long does the pharmacokinetic interaction between carbamazepine and quetiapine last after carbamazepine withdrawal? Neuro Endocrinol Lett. 2017; 38: 475-478.


Selected or ongoing grants/clinical studies

2020-2026: TheraLymph –Gene Therapy to restore lymphatic flow lymphedema, H2020 SC1-BHC-07-2019, Project # 874708


2021-2024: Novel approaches to enhance insulin-sensitizing effects of exercise: targeting PAHSA metabolism ETAPA; Czech Health Research Council project NU21-01-00469


2019 - 2022: Pancreatic cancer: metabolic derangements assiocated with insulin resistence (PAMIR), Czech Health Research Council project NV19-01-00101, Co-PI: Lenka Rossmeislova




Last change: October 3, 2022 10:05 
Share on: Facebook Share on: Twitter
Share on:  
Contacts

Third Faculty of Medicine

Charles University

Ruská 87, 100 00 Prague 10

Czech Republic


Phone.: +420 267 102 111


Data Box ID: piyj9b4

ID No.: 00216208, VAT No.: CZ00216208


How to reach us


Your opinion